Article Text

other Versions

PDF
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies
  1. Paul F Worth1,2
  1. 1Department of Neurology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK
  2. 2University of East Anglia, Norwich, UK
  1. Correspondence to Dr Paul F Worth, Department of Neurology, Norfolk and Norwich Hospital NHS Foundation Trust, Colney Lane, Norwich NR4 7UY, UK; paul.worth{at}nnuh.nhs.uk

Abstract

Levodopa-induced motor complications of Parkinson's disease, including motor fluctuations and dyskinesias, become increasingly frequent as the disease progresses, and are often disabling. Oral and transdermal therapies have limited efficacy in controlling these problems. Advanced device-aided therapies, including continuous infusion of apomorphine, deep brain stimulation and levodopa-carbidopa intestinal gel can all ameliorate these complications. This review summarises the principles of each of these therapies, their modes of action, efficacy and adverse effects, and gives advice on timely identification of suitable patients and how to decide on the most appropriate therapy for a given patient.

  • Parkinson-s disease

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.